Vanda Pharmaceuticals (VNDA) EBT (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly EBT of -$48.4 million in Q1 2026, down 27.42% quarter-over-quarter from -$38.0 million in Q4 2025, and down 29.59% year-over-year from -$68.8 million in Q1 2025.
Vanda Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at -$48.4 million for Q1 2026.
- In Q1 2026, EBT fell 29.59% year-over-year to -$48.4 million; the TTM figure through Mar 2026 stood at -$149.7 million (down 169.13% YoY), while the FY2025 annual figure was -$138.6 million, down 504.89% from the prior year.
- EBT came in at -$48.4 million for Q1 2026 at Vanda Pharmaceuticals, down from -$38.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of $9.6 million in Q4 2022 to a low of -$48.4 million in Q1 2026.
- A 5-year average of -$11.3 million and a median of -$5.5 million in 2024 frame the typical range for EBT.
- Across the five-year window, EBT jumped 173.08% in 2023 and slumped 5103.33% in 2024, its largest moves.
- Vanda Pharmaceuticals' EBT stood at $9.6 million in 2022, then tumbled by 117.28% to -$1.7 million in 2023, then slumped by 291.15% to -$6.5 million in 2024, then slumped by 484.92% to -$38.0 million in 2025, then declined by 27.42% to -$48.4 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$48.4 million, -$38.0 million, and -$28.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -48.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.42 Mn |
| Dec 31, 2025 | -38.00 Mn |
| Sep 30, 2025 | -28.39 Mn |
| Jun 30, 2025 | -34.89 Mn |
| Mar 31, 2025 | -37.37 Mn |
| Dec 31, 2024 | -6.50 Mn |
| Sep 30, 2024 | -6.24 Mn |
| Jun 30, 2024 | -5.52 Mn |
| Mar 31, 2024 | -4.66 Mn |
| Dec 31, 2023 | -1.66 Mn |
| Sep 30, 2023 | -120,000.00 |
| Jun 30, 2023 | 2.59 Mn |
| Mar 31, 2023 | 5.53 Mn |
| Dec 31, 2022 | 9.61 Mn |
| Sep 30, 2022 | 5.46 Mn |
| Jun 30, 2022 | 3.79 Mn |
| Mar 31, 2022 | -7.56 Mn |
| Dec 31, 2021 | 8.61 Mn |
| Sep 30, 2021 | 10.72 Mn |
| Jun 30, 2021 | 12.60 Mn |
| Mar 31, 2021 | 10.43 Mn |
| Dec 31, 2020 | 10.92 Mn |
| Sep 30, 2020 | 8.40 Mn |
| Jun 30, 2020 | 11.09 Mn |
| Mar 31, 2020 | 1.24 Mn |
| Dec 31, 2019 | 5.81 Mn |
| Sep 30, 2019 | 12.28 Mn |
| Jun 30, 2019 | 11.54 Mn |
| Mar 31, 2019 | -602,000.00 |
| Dec 31, 2018 | 10.32 Mn |
| Sep 30, 2018 | 7.26 Mn |
| Jun 30, 2018 | 4.70 Mn |
| Mar 31, 2018 | 3.06 Mn |
| Dec 31, 2017 | -1.75 Mn |
| Sep 30, 2017 | -4.53 Mn |
| Jun 30, 2017 | -1.53 Mn |
| Mar 31, 2017 | -7.63 Mn |
| Dec 31, 2016 | -500,000.00 |
| Sep 30, 2016 | -430,000.00 |
| Jun 30, 2016 | -4.62 Mn |
| Mar 31, 2016 | -12.36 Mn |
| Dec 31, 2015 | -14.89 Mn |
| Sep 30, 2015 | -9.54 Mn |
| Jun 30, 2015 | -5.46 Mn |
| Mar 31, 2015 | -10.29 Mn |
| Dec 31, 2014 | 69.69 Mn |
| Sep 30, 2014 | -1.45 Mn |
| Jun 30, 2014 | -21.58 Mn |
| Mar 31, 2014 | -26.53 Mn |
| Dec 31, 2013 | -7.62 Mn |
| Sep 30, 2013 | -5.38 Mn |
| Jun 30, 2013 | -3.38 Mn |
| Mar 31, 2013 | -4.52 Mn |
| Dec 31, 2012 | 20.34 Mn |
| Sep 30, 2012 | -5.33 Mn |
| Jun 30, 2012 | -8.01 Mn |
| Mar 31, 2012 | -7.96 Mn |
| Dec 31, 2011 | -5.81 Mn |
| Sep 30, 2011 | -3.19 Mn |
| Jun 30, 2011 | -1.39 Mn |
| Mar 31, 2011 | 142,000.00 |
| Dec 31, 2010 | 933,000.00 |
| Sep 30, 2010 | 899,000.00 |
| Jun 30, 2010 | 1.24 Mn |